Premium
Three‐day lansoprazole quadruple therapy for Helicobacter pylori ‐positive duodenal ulcers: a randomized controlled study
Author(s) -
Wong B. C. Y.,
Wang W. H.,
Wong W. M.,
Lau G. K. K.,
Fung F. M. Y.,
Kung N. N. S.,
Chu K. M.,
Lai K. C.,
Hu W. H. C.,
Hu F. L.,
Liu X. G.,
Chan C. K.,
Yuen M. F.,
Hui W. M.,
Lam S. K.
Publication year - 2001
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1046/j.1365-2036.2001.00999.x
Subject(s) - lansoprazole , medicine , metronidazole , clarithromycin , tolerability , gastroenterology , helicobacter pylori , randomized controlled trial , surgery , antibiotics , adverse effect , microbiology and biotechnology , biology
Aim: To compare the efficacy and tolerability of a 3‐day quadruple therapy with a standard 7‐day triple therapy in eradicating Helicobacter pylori infection and healing duodenal ulcers. Methods: Patients with H. pylori ‐positive duodenal ulcers were randomized to receive either lansoprazole 30 mg, clarithromycin 500 mg, and metronidazole 400 mg twice daily for 7 days (LCM‐7) or lansoprazole 30 mg, clarithromycin 500 mg, metronidazole 400 mg, and bismuth subcitrate 240 mg twice daily for 3 days (LCMB‐3). No pre‐ or post‐treatment acid suppression was used. Follow‐up endoscopy was performed at week 6. Results: A total of 118 patients were recruited. Sixty patients in the LCM‐7 group and 53 patients in the LCMB‐3 group returned for endoscopy. Intention‐to‐treat eradication rates were 87% and 86% ( P =0.94) and per protocol eradication rates were 87% and 94% ( P =0.29) in the LCM‐7 and LCMB‐3 groups, respectively. Per protocol and intention‐to‐treat ulcer healing rates were 98% and 98% in LCM‐7 and 100% and 91% in LCMB‐3, respectively. There were no significant differences in efficacy in relation to the initial metronidazole and clarithromycin susceptibility. Significant reduction in the duration of side‐effects was found in the LCMB‐3 group. Conclusion: The 3‐day quadruple therapy is highly effective, better tolerated and can be considered as a first‐line therapy in duodenal ulcer management.